Skip to main content
Caplight Logo









Proxygen

Proxygen

Private
ViennaHealthcare & Life Scienceshttps://proxygen.com/

Last Round

Strategic

Apr 5, 2023

Total Funding Raised

$250,000

Company Overview

Proxygen is a biotechnology company developing a new class of therapeutics based on induced proximity to address high-value targets in oncology and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

molecular glue degradersmolecular glue discoveryundruggable targetsdrug discovery platformtargeted protein degradationTPDinduced proximitypharmaceutical partnershipssmall molecule drugsprotein degradationcancer therapeuticsdrug licensingproteomicsAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Proxygen Comparables

Compare Proxygen with similar companies based on industry and business-model similarity.

Proxygen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neomorph
89%
Degron Therapeutics
88%
Plexium
88%

Proxygen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicApr 5, 2023
StrategicJun 2, 2022
StrategicDec 7, 2020
GrantJul 31, 2020

Key People

Founding team and executive leadership

Matthias Brand

Chief Technology Officer, Co-founder, Chief Scientific Officer, Co-founder

Founding Team

Bernd Boidol

CEO

Executive Team

Proxygen Investors

Notable investors and investment history

Proxygen investors
InvestorRounds
Boehringer IngelheimGrant, Strategic
WlanholdingSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors grew 49% MoM.

  • Aug 8, 2023

    Grew 30% QoQ, from 23 to 30 employees.

Proxygen Filings

Explore SEC and related filing metadata, where available.

Proxygen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Proxygen's valuation, stock price, and market status.

Is Proxygen a public or private company?

Proxygen is a private company.

What is the current stock price of Proxygen?

Proxygen is a private company with no public stock price. No recent secondary market data is available.

How much is Proxygen worth (valuation)?

Valuation information for Proxygen is not publicly available.

Can I buy Proxygen stock?

Proxygen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Proxygen's last funding round?

Proxygen's most recent funding round was Strategic on April 5, 2023.

Who are the main investors in Proxygen?

Key investors in Proxygen include Boehringer Ingelheim, Wlanholding.

Will Proxygen IPO soon?

No public IPO plans have been announced for Proxygen.

How can I track Proxygen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Proxygen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVienna
Employee Range36
Year Founded2020
Last FundingApr 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?